50KRW
3.51 BKRW
134.91 BKRW
29.77 M
About HANALL BIOPHARMA
Sector
Headquarters
Daejeon
Founded
1973
Website
ISIN
KR7009420001
FIGI
BBG000BG01Z0
HANALL BIOPHARMA Co., Ltd. engages in the manufacture and sale of synthetic drug and biopharmaceuticals. It offers products such as medicine for digestion, high blood pressure, cerebrovascular disease, myocardial infarction, anti-diabetics, antibiotics, gastrointestinal, bone structure, erectile dysfunction, hives, and other pharmaceutical products. The company was founded by Byeong-Tae Kim on November 20, 1973 and is headquartered in Daejeon, South Korea.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 009420 is 32 650 KRW — it has decreased by 0.76% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange HANALL BIOPHARMA stocks are traded under the ticker 009420.
One year price forecast for HANALL BIOPHARMA has a max estimate of 46 000 KRW and a min estimate of 45 000 KRW.
HANALL BIOPHARMA revenue for the last quarter amounts to 32.60 B KRW despite the estimated figure of 33.15 B KRW. In the next quarter revenue is expected to reach 32.95 B KRW.
Yes, you can track HANALL BIOPHARMA financials in yearly and quarterly reports right on TradingView.
Like other stocks, 009420 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HANALL BIOPHARMA stock right from TradingView charts — choose your broker and connect to your account.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HANALL BIOPHARMA EBITDA is 4.99 B KRW, and current EBITDA margin is 3.70%. See more stats in HANALL BIOPHARMA financial statements.